一个复杂的 Polycomb 问题：EZH2 在癌症中的双重面目。
A complex Polycomb issue: the two faces of EZH2 in cancer.
机构信息
Cancer Center, Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
出版信息
Genes Dev. 2012 Apr 15;26(8):751-5. doi: 10.1101/gad.191163.112.
Abstract
In the April 1, 2012, issue of Genes & Development, Simon and colleagues (pp. 651-656) demonstrated that the disruption of Ezh2 in mice is sufficient to cause T-acute lymphoblastic leukemia (T-ALL). Moreover, in concert with concurrent studies, the authors revealed that similar mechanisms are involved in human T-ALL. These data contrast with previous findings showing that increased EZH2 activity promotes cancer.
摘要
在 2012 年 4 月 1 日的《基因与发育》杂志上，Simon 及其同事（第 651-656 页）证明，破坏小鼠中的 Ezh2 足以导致 T 急性淋巴细胞白血病（T-ALL）。此外，与同期研究结果一致，作者揭示了类似的机制也涉及人类 T-ALL。这些数据与先前的发现形成对比，先前的发现表明增加 EZH2 活性会促进癌症。
相似文献
1
A complex Polycomb issue: the two faces of EZH2 in cancer.一个复杂的 Polycomb 问题：EZH2 在癌症中的双重面目。
Genes Dev. 2012 Apr 15;26(8):751-5. doi: 10.1101/gad.191163.112.
2
A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia.EZH2 及其相关基因在鼠和人急性 T 细胞白血病中的关键作用。
Genes Dev. 2012 Apr 1;26(7):651-6. doi: 10.1101/gad.186411.111. Epub 2012 Mar 19.
3
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.组蛋白去乙酰化酶抑制剂可使人类急性白血病细胞中的zeste 2增强子及相关的多梳抑制复合物2蛋白减少。
Mol Cancer Ther. 2006 Dec;5(12):3096-104. doi: 10.1158/1535-7163.MCT-06-0418.
4
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).组蛋白甲基转移酶 EZH2 的 A677 突变促进了人类 B 细胞淋巴瘤中组蛋白 H3 赖氨酸 27（H3K27）的超三甲基化。
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2989-94. doi: 10.1073/pnas.1116418109. Epub 2012 Feb 8.
5
Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells.组蛋白甲基转移酶EZH2的下调有助于人子宫内膜基质细胞蜕膜化的表观遗传编程。
Mol Endocrinol. 2011 Nov;25(11):1892-903. doi: 10.1210/me.2011-1139. Epub 2011 Sep 8.
6
Substrate preferences of the EZH2 histone methyltransferase complex.EZH2组蛋白甲基转移酶复合物的底物偏好性。
J Biol Chem. 2006 Mar 31;281(13):8365-70. doi: 10.1074/jbc.M513425200. Epub 2006 Jan 23.
7
Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells.依赖于多梳基因 Ezh2 可区分胎儿和成体造血干细胞。
Blood. 2011 Dec 15;118(25):6553-61. doi: 10.1182/blood-2011-03-340554. Epub 2011 Oct 31.
8
FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway.成纤维细胞生长因子 2 通过 NDY1/KDM2B- miR-101-EZH2 通路调节细胞增殖、迁移和血管生成。
Mol Cell. 2011 Jul 22;43(2):285-98. doi: 10.1016/j.molcel.2011.06.020.
9
Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.组蛋白 H3 赖氨酸 27 三甲基化的增强子结合蛋白 2 在成人 T 细胞白血病/淋巴瘤中的过表达作为表观遗传学治疗的靶点。
Haematologica. 2011 May;96(5):712-9. doi: 10.3324/haematol.2010.028605. Epub 2011 Jan 12.
10
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.组蛋白甲基转移酶EZH2抑制剂3-去氮杂氮胞苷A与组蛋白去乙酰化酶抑制剂帕比司他联合用于抗人急性髓系白血病细胞的表观遗传治疗。
Blood. 2009 Sep 24;114(13):2733-43. doi: 10.1182/blood-2009-03-213496. Epub 2009 Jul 28.
引用本文的文献
1
HDAC7 induction combined with standard-of-care chemotherapy provides a therapeutic advantage in t(4;11) infant B-cell acute lymphoblastic leukemia.组蛋白去乙酰化酶7诱导联合标准护理化疗在t(4;11) 婴儿B细胞急性淋巴细胞白血病中具有治疗优势。
Biomark Res. 2025 Jul 28;13(1):99. doi: 10.1186/s40364-025-00810-1.
2
The Antitumour Mechanisms of Carotenoids: A Comprehensive Review.类胡萝卜素的抗肿瘤机制：综述
Antioxidants (Basel). 2024 Aug 30;13(9):1060. doi: 10.3390/antiox13091060.
3
Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression.代谢重编程受 TRAF6 调控，促进白血病进展。
Leukemia. 2024 May;38(5):1032-1045. doi: 10.1038/s41375-024-02245-3. Epub 2024 Apr 12.
4
EZH2 Inhibition Sensitizes IDH1R132H-Mutant Gliomas to Histone Deacetylase Inhibitor.EZH2 抑制使 IDH1R132H 突变型神经胶质瘤对组蛋白去乙酰化酶抑制剂敏感。
Cells. 2024 Jan 25;13(3):219. doi: 10.3390/cells13030219.
5
Comparative analysis of EZH2, p16 and p53 expression in uterine carcinosarcomas.子宫癌肉瘤中 EZH2、p16 和 p53 表达的比较分析。
Pathol Oncol Res. 2023 Dec 11;29:1611547. doi: 10.3389/pore.2023.1611547. eCollection 2023.
6
Downregulation of EZH2 inhibits epithelial-mesenchymal transition in enzalutamide-resistant prostate cancer.下调 EZH2 抑制恩杂鲁胺耐药前列腺癌中的上皮间质转化。
Prostate. 2023 Nov;83(15):1458-1469. doi: 10.1002/pros.24602. Epub 2023 Jul 20.
7
Epigenetics and immune cells in medulloblastoma.髓母细胞瘤中的表观遗传学与免疫细胞
Front Genet. 2023 Mar 10;14:1135404. doi: 10.3389/fgene.2023.1135404. eCollection 2023.
8
PAR-Induced Harnessing of EZH2 to β-Catenin: Implications for Colorectal Cancer.PAR 诱导的 EZH2 对 β-连环蛋白的利用：对结直肠癌的影响。
Int J Mol Sci. 2022 Aug 6;23(15):8758. doi: 10.3390/ijms23158758.
9
PRC2 Heterogeneity Drives Tumor Growth in Medulloblastoma.PRC2 异质性驱动髓母细胞瘤生长。
Cancer Res. 2022 Aug 16;82(16):2874-2886. doi: 10.1158/0008-5472.CAN-21-4313.
10
An EZH2 blocker sensitizes histone mutated diffuse midline glioma to cholesterol metabolism inhibitors through an off-target effect.一种EZH2阻断剂通过脱靶效应使组蛋白突变的弥漫性中线胶质瘤对胆固醇代谢抑制剂敏感。
Neurooncol Adv. 2022 Mar 1;4(1):vdac018. doi: 10.1093/noajnl/vdac018. eCollection 2022 Jan-Dec.
本文引用的文献
1
A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia.EZH2 及其相关基因在鼠和人急性 T 细胞白血病中的关键作用。
Genes Dev. 2012 Apr 1;26(7):651-6. doi: 10.1101/gad.186411.111. Epub 2012 Mar 19.
2
A functional role for the histone demethylase UTX in normal and malignant hematopoietic cells.组蛋白去甲基化酶 UTX 在正常和恶性造血细胞中的功能作用。
Exp Hematol. 2012 Jun;40(6):487-98.e3. doi: 10.1016/j.exphem.2012.01.017. Epub 2012 Feb 1.
3
Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies.表观遗传学标记物和表观遗传学分析在髓系恶性肿瘤中的临床应用。
Semin Oncol. 2012 Feb;39(1):109-22. doi: 10.1053/j.seminoncol.2011.11.003.
4
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.儿童弥漫性内在脑桥神经胶质瘤和非脑干部位神经胶质瘤中的体干细胞组蛋白 H3 改变。
Nat Genet. 2012 Jan 29;44(3):251-3. doi: 10.1038/ng.1102.
5
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.组蛋白 H3.3 和染色质重塑基因中的驱动突变与儿童弥漫性脑桥胶质瘤。
Nature. 2012 Jan 29;482(7384):226-31. doi: 10.1038/nature10833.
6
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.T 细胞急性淋巴细胞白血病中多梳抑制复合物 2 的遗传失活。
Nat Med. 2012 Feb 6;18(2):298-301. doi: 10.1038/nm.2651.
7
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.早期 T 细胞前体急性淋巴细胞白血病的遗传基础。
Nature. 2012 Jan 11;481(7380):157-63. doi: 10.1038/nature10725.
8
A mutation in the E(Z) methyltransferase that increases trimethylation of histone H3 lysine 27 and causes inappropriate silencing of active Polycomb target genes.E(Z) 甲基转移酶中的突变会增加组蛋白 H3 赖氨酸 27 的三甲基化，并导致活性 Polycomb 靶基因的不当沉默。
Dev Biol. 2012 Apr 15;364(2):249-58. doi: 10.1016/j.ydbio.2011.12.007. Epub 2011 Dec 11.
9
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.多梳抑制复合物 2 成分在骨髓增生性和骨髓增生异常/骨髓增生性肿瘤中的失活。
Blood. 2012 Feb 2;119(5):1208-13. doi: 10.1182/blood-2011-07-367243. Epub 2011 Nov 3.
10
Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells.依赖于多梳基因 Ezh2 可区分胎儿和成体造血干细胞。
Blood. 2011 Dec 15;118(25):6553-61. doi: 10.1182/blood-2011-03-340554. Epub 2011 Oct 31.
Zotero 插件